Skip to content

Onxeo Signs Exclusive License Agreement with Pint Pharma for the Commercialization of Beleodaq® in PTCL in South America

  • Agreement covering seven South American countries
  • Onxeo to receive upfront payment, regulatory and commercial milestones, and sales royalties for a total deal value greater than USD 20 million

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specialized in the development of orphan oncology therapeutics, today announced it has entered into an exclusive license agreement with Pint Pharma for the commercialization of Beleodaq® (belinostat), Onxeo’s pan-HDAC inhibitor for PTCL (peripheral T-cell lymphoma), in key South American countries. Beleodaq® is approved in the US, and has been marketed by Spectrum Pharmaceuticals since July 2014 as a 2nd-line treatment for PTCL.

Pint Pharma is a private specialty pharma company well experienced in commercializing orphan drugs and highly specialized products in South American healthcare markets.

Under the terms of the agreement, Pint Pharma will register, commercialize, and promote Beleodaq® in seven countries: Argentina, Brazil, Chile, Colombia, Ecuador, Peru, and Venezuela.

Onxeo will receive an upfront payment from Pint Pharma, regulatory and commercial milestone as well as double-digit royalties on the net sales of Beleodaq® in these territories, representing a deal value of over USD 20 million.

“We are extremely pleased to announce this exclusive licensing agreement for Beleodaq®, and to have Pint Pharma as a strategic partner in South America. This is the second Beleodaq® licensing agreement, demonstrating our product’s commercial potential as well as its clinical value. We look forward to a close collaboration with Pint Pharma as we leverage their team’s strong expertise in this region to provide access to our treatment to a greater number of PTCL patients,”commented Judith Greciet, CEO of Onxeo.

While initiating the regulatory procedures to obtain market approval, Pint Pharma also plans to make Beleodaq® available to PTCL patients through Early Access Programs (EAPs) in eligible countries by the end of 2016.

“This collaboration agreement with Onxeo is a great opportunity for us to expand our hematology franchise and strengthen our leadership position in the South American oncology market. We are thrilled to be working with Onxeo, a company that shares our values and commitment to making innovative therapeutics available to patients suffering from rare diseases,” commented David Muñoz, CEO of Pint Pharma.